Alembic Pharma share price jumps 12% after USFDA approval for cancer drug
Shares of Alembic Pharmaceuticals Ltd rallied more than 12 per cent on Monday after the company received final approval from the US Food and Drug Administration (USFDA) for its generic Doxorubicin Hydrochloride Liposome Injection, a cancer treatment drug. The stock climbed to an intraday high of Rs 1,086.7 on the NSE. Over the past month,…